Multimodal treatment combining neoadjuvant therapy, laparoscopic subtotal distal pancreatectomy and adjuvant therapy for pancreatic neck-body cancer: Case series

Table 1 Patients baseline information and results of neoadjuvant therapy, n (%)

Characteristic	N = 11
Sex
Female	6 (55)
Male	5 (45)
Age (years), median (range)	55 (41-68)
Blood glucose level
Normal	6 (55)
Diabetes	4 (36)
Impaired glucose tolerance	1 (9)
Before neoadjuvant therapy
Borderline	6 (55)
Locally advanced	5 (45)
Arterial involvement
CA	1 (9)
CA/SMA	5 (45)
CHA/CA	3 (27.3)
CHA/CA/SMA	1 (9.1)
SMA	1 (9.1)
Vein involvement
PV/SMV/SV	8 (73)
PV/SV	3 (27)
Biopsy
Ductal adenocarcinoma	11 (100)
Neoadjuvant therapy regimen
AG	6 (55)
AG + tirelizumab	1 (9)
AG + S-1 + tirelizumab	1 (9)
The mFOLFIRINOX	3 (27)
Neoadjuvant therapy cycle, median (range)	5 (2-6)
Initial CA19-9 (U/mL), median (range)	871 (112-2154)
Preoperative CA19-9 (U/mL), median (range)	24 (6-157)
Initial diameter (cm), median (range)	4.4 (2.8-5.9)
Preoperative diameter (cm), median (range)	2.2 (1.3-4.1)
Neoadjuvant therapy effect
PR	8 (73)
SD	3 (27)
After neoadjuvant therapy
Borderline	8 (73)
Resectable	3 (27)

CA: Celiac artery; SMA: Superior mesenteric artery; CHA: Common hepatic artery; PV: Portal vein; SMV: Superior mesenteric vein; SV: Spleen vein; AG: Albumin-bound paclitaxel and gemcitabine; S-1: Tegafur, gimeracil, and oteracil potassium; mFOLFIRINOX: Modified FOLFIRINOX regimen, including 5-fluorouracil, leucovorin, irinotecan and oxaliplatin; CA19-9: Carbohydrate antigen 19-9; PR: Partial response; SD: Stable disease.